Navigation Links
Nanogea Announces New Scientific Advisory Board Members
Date:10/9/2009

Nanogea Adds Drs. C. Thomas Caskey and Saul Tendler to its Scientific Advisory Board

Westlake Village, Calif. (PRWEB) October 9, 2009 -- Nanogea, a nano-biotech company focused on commercializing the industry's most sensitive single molecular detection platform, is pleased to announce today that Dr. C. Thomas Caskey and Dr. Saul Tendler have joined its scientific advisory board.

Dr. Caskey is a prominent medical geneticist and biomedical entrepreneur. Dr. Caskey presently serves as Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, a research institute that seeks to investigate the cause of human diseases at the cellular and molecular levels using DNA and protein technologies to expose disease mechanisms. He is a former founding Director and CEO of Cogene Biotech Ventures, venture capital funds designed to support early-stage biotechnology and life science companies. Dr. Caskey is a former SVP for Res. at Merck and Trustee and President of the Merck Genome Res. Inst. as well as an Ex-Chief of Section of Medical Genetics and Professor of Medicine and Biochemistry, Baylor College of Medicine. He sits on the boards of Essex Woodlands Health Ventures, Luminex, Odyssey Thera, En Vivo, Metabolon, Genome Canada, LabCorp. of America, and Vice Chair of Genome Canada. Dr. Caskey is a member of the Academy of Medicine, Engineering and Science of Texas (President of TAMEST 2004-05), a member of the National Academy of Sciences, and the Institute of Medicine. Dr. Caskey received his medical doctorate from Duke University. He is Board certified in Internal Medicine, Clinical Genetics, Metabolic Diseases, and Molecular Diagnostics.

Dr. Saul Tendler is Pro-Vice-Chancellor, Professor of Biophysical Chemistry and Head of the School of Pharmacy, University of Nottingham. His expertise is in the field of biophysical chemistry, with a particular focus on analysis of biomolecular systems and their interactions. Dr. Tendler is a Fellow of the Royal Society of Chemistry, and was designated a Fellow of the Royal Pharmaceutical Society of Great Britain in 2000. Dr. Tendler received his Ph.D. from the University of Aston and his Bachelors of Science (First Class Honours) in Pharmacy at the University of Manchester.

"We are delighted to have a distinguished panel of advisors such as Drs. Caskey and Tendler," said Mr. David Sun, President and CEO of Nanogea, "Their extraordinary expertise and background will help guide Nanogea's research and development in the foreseeable future as we expedite our development effort to commercialize our first clinical application for CML (Chronic Myelogeous Leukemia) detection, based on our proprietary NanoCone™ chemistry and NE-AFM™ platform."

About Nanogea
Nanogea, a nano-biotech company located in Westlake Village California, is focused on commercializing the industry's most sensitive genomic and proteomic detection platform based on its innovative NanoCone™ chemistry and NanoCone Enabled Atomic Force Microscopy (NE-AFM™ ) technology. The Company is utilizing its technology to push the genetic and protein detection limit to the single molecular level, thus greatly improving the sensitivity and accuracy of disease diagnosis, prognosis, treatment, and monitoring as well as drug discovery research. To learn more about our pioneering technology, visit www.nanogea.com.

Nanogea Corporation
5716 Corsa Avenue, Suite 201
Westlake Village, CA 91362.
Phone: (818) 889-0538    Fax: (818) 889-0816
E-mail: mlowrey(at)nanogea(dot)com
Website: www.nanogea.com

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3017444.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors
2. IridoTech Announces IridoLab Self Service Kiosk
3. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
4. NCIIA Announces New Undergraduate Competition
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
7. Verenium Announces Proposed Public Offering of Common Stock
8. Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
9. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
10. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
11. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):